Polymorphism of μ1-opioid receptor (OPRM1) gene may be of value in genesis of renal malignant neoplasm
A. L. Potapov,
A. D. Kaprin,
S. A. Ivanov,
A. V. Boiarkina,
N. Yu. Novikov,
R. R. Gevorkyan,
I. P. Kostyuk https://doi.org/10.17650/1726-9776-2019-15-3-42-45
Abstract
Objective: to evaluate alleles distribution of single nucleotide polymorphism 118A>G of μ1-opioid receptor (OPRM1) gene in patients with renal neoplasm and benign diseases.
Materials and methods. 100 consecutive patients after renal surgeries retrospectively divided into groups with neoplasm (n = 29) and benign diseases (n = 71).
Results. The incidence of renal neoplasm was much higher in homozygous 118A patients than in AG + GG group (36.4 % vs. 14.7 %; p = 0.035).
Conclusion. Single nucleotide polymorphism 118A>G OPRM1 gene may be of value in genesis of renal neoplasm.
About the Authors
A. L. Potapov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Koroleva St., Obninsk 249031
A. D. Kaprin
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
4 Koroleva St., Obninsk 249031
S. A. Ivanov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
4 Koroleva St., Obninsk 249031
A. V. Boiarkina
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
4 Koroleva St., Obninsk 249031
N. Yu. Novikov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
4 Koroleva St., Obninsk 249031
R. R. Gevorkyan
N.A. Semashko Republican Clinical Hospital
69 Kievskaya St., Simferopol 295034
I. P. Kostyuk
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
4 Koroleva St., Obninsk 249031
References
1. Singleton P.A., Mirzapoiazova T., Hasina R. et al. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth 2014;113(Suppl 1):i103–8. DOI: 10.1093/bja/aeu165.
2. Yao Y.S., Yao R.Y., Zhuang L.K. et al. MOR1 expression in gastric cancer: a biomarker associated with poor outcome. Clin Transl Sci 2015;8(2):137–42. DOI: 10.1111/cts.12246.
3. Zylla D., Gourley B.L., Vang D. et al. Opioid requirement, opioid receptor expression and clinical outcomes in patients with advanced prostate cancer. Cancer 2013;119(23):4103–10. DOI: 10.1002/cncr.28345.
4. Singleton P., Moss J., Karp D. et al. The mu opioid receptor: a new target for cancer therapy? Cancer 2015;121(16):2681–8. DOI: 10.1002/cncr.29460.
5. Mura E., Govony S., Racchi M. et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Research 2013;6:331–53. DOI: 10.2147/JPR.S42040.
6. Wang S., Li Y., Liu X. et al. Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol 2013;18(4):666–9. DOI: 10.1007/s10147-012-0441-5.
7. Bortsov A., Millikan R., Belfer I. et al. μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012;116(4):896–902. DOI: 10.1097/ALN.0b013e31824b96a1.
8. Cieślińska A., Sienkiewicz-Szłapka E., Kostyra E. et al. μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer. Tumor Biol. 2015; 36(6):4655–60. DOI: 10.1007/s13277015-3113-z.
9. Oh C.S., Lee S.H., Yoo Y.B. et al. Muopioid receptor polymorphisms and breast cancer in a korean female adult population: a retrospective study. J Breast Cancer 2016;19(2):206–9. DOI: 10.4048/jbc.2016.19.2.206.
10. Potapov A.L., Boiarkina A.V. Μ1-opioid receptor and catechol-o-metiltransferase genes polymorphism effects on periop erative psychological condition of the patients and the effectiveness of postoperative analgesia with opioids. Aneste ziologiya i reanimatologiya = Anesthesiology and Reanimatology 2015;3:48–51. (In Russ.).
11. Malignant tumors in Russia in 2015 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2017. 250 p. (In Russ.).
12. Bar-Shavit R., Maoz M., Kancharla A. et al. G protein-coupled receptors in cancer. Int J Mol Sci 2016;17(8):1320. DOI: 10.3390/ijms17081320.
13. Gach K., Wyrebska A., Fichna J., Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol 2011;384(3):221–30. DOI: 10.1007/s00210-011-0672-4.
14. Jorand R., Biswas S., Wakefield D.L. et al. Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell 2016;27(22):3659–72. DOI: 10.1091/mbc.E16-06-0427.
Review
For citations:
Potapov A.L., Kaprin A.D., Ivanov S.A., Boiarkina A.V., Novikov N.Yu., Gevorkyan R.R., Kostyuk I.P. Polymorphism of μ1-opioid receptor (OPRM1) gene may be of value in genesis of renal malignant neoplasm. Cancer Urology. 2019;15(3):42-45. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-3-42-45
Views:
962
Email this article 